Toppgene analysis for Wikipedia protein communities, toppgene analysis, cc433_6, positive side

Go To Start Page
Input Parameters [Show Detail]
Training Results [Expand All] [Download All] [Sparse Matrix]
Display pValues and Scores as Table row limit

1: GO: Molecular Function [Display Chart] 6 input genes in category / 32 annotations before applied cutoff / 18661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0031625 ubiquitin protein ligase binding 3.077E-3 4.115E-2
1.670E-1
9.846E-2
 2 273
2 GO:0044389 ubiquitin-like protein ligase binding 3.166E-3 4.115E-2
1.670E-1
1.013E-1
 2 277
3 GO:0000983 transcription factor activity, RNA polymerase II core promoter sequence-specific DNA binding 4.494E-3 4.115E-2
1.670E-1
1.438E-1
 1 14
4 GO:0000978 RNA polymerase II proximal promoter sequence-specific DNA binding 5.846E-3 4.115E-2
1.670E-1
1.871E-1
 2 379
5 GO:0000987 proximal promoter sequence-specific DNA binding 6.430E-3 4.115E-2
1.670E-1
2.058E-1
 2 398

2: GO: Biological Process [Display Chart] 6 input genes in category / 450 annotations before applied cutoff / 18623 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0090303 positive regulation of wound healing 1.183E-4 2.557E-2
1.710E-1
5.325E-2
 2 53
2 GO:0090096 positive regulation of metanephric cap mesenchymal cell proliferation 3.222E-4 2.557E-2
1.710E-1
1.450E-1
 1 1
3 GO:0090095 regulation of metanephric cap mesenchymal cell proliferation 3.222E-4 2.557E-2
1.710E-1
1.450E-1
 1 1
4 GO:0046722 lactic acid secretion 3.222E-4 2.557E-2
1.710E-1
1.450E-1
 1 1
5 GO:0044330 canonical Wnt signaling pathway involved in positive regulation of wound healing 6.443E-4 2.557E-2
1.710E-1
2.899E-1
 1 2
6 GO:0072185 metanephric cap development 6.443E-4 2.557E-2
1.710E-1
2.899E-1
 1 2
7 GO:0090094 metanephric cap mesenchymal cell proliferation involved in metanephros development 6.443E-4 2.557E-2
1.710E-1
2.899E-1
 1 2
8 GO:0072186 metanephric cap morphogenesis 6.443E-4 2.557E-2
1.710E-1
2.899E-1
 1 2
9 GO:0061041 regulation of wound healing 7.790E-4 2.557E-2
1.710E-1
3.506E-1
 2 136
10 GO:0009411 response to UV 8.252E-4 2.557E-2
1.710E-1
3.713E-1
 2 140
11 GO:0000432 positive regulation of transcription from RNA polymerase II promoter by glucose 9.663E-4 2.557E-2
1.710E-1
4.348E-1
 1 3
12 GO:0044337 canonical Wnt signaling pathway involved in positive regulation of apoptotic process 9.663E-4 2.557E-2
1.710E-1
4.348E-1
 1 3
13 GO:0000430 regulation of transcription from RNA polymerase II promoter by glucose 9.663E-4 2.557E-2
1.710E-1
4.348E-1
 1 3
14 GO:0072133 metanephric mesenchyme morphogenesis 1.288E-3 2.557E-2
1.710E-1
5.797E-1
 1 4
15 GO:0019086 late viral transcription 1.288E-3 2.557E-2
1.710E-1
5.797E-1
 1 4
16 GO:0000320 re-entry into mitotic cell cycle 1.288E-3 2.557E-2
1.710E-1
5.797E-1
 1 4
17 GO:0000429 carbon catabolite regulation of transcription from RNA polymerase II promoter 1.288E-3 2.557E-2
1.710E-1
5.797E-1
 1 4
18 GO:0072131 kidney mesenchyme morphogenesis 1.288E-3 2.557E-2
1.710E-1
5.797E-1
 1 4
19 GO:0002904 positive regulation of B cell apoptotic process 1.288E-3 2.557E-2
1.710E-1
5.797E-1
 1 4
20 GO:0046016 positive regulation of transcription by glucose 1.288E-3 2.557E-2
1.710E-1
5.797E-1
 1 4
21 GO:0000436 carbon catabolite activation of transcription from RNA polymerase II promoter 1.288E-3 2.557E-2
1.710E-1
5.797E-1
 1 4
22 GO:0031669 cellular response to nutrient levels 1.358E-3 2.557E-2
1.710E-1
6.113E-1
 2 180
23 GO:1903036 positive regulation of response to wounding 1.481E-3 2.557E-2
1.710E-1
6.662E-1
 2 188
24 GO:2001235 positive regulation of apoptotic signaling pathway 1.559E-3 2.557E-2
1.710E-1
7.017E-1
 2 193
25 GO:0006848 pyruvate transport 1.610E-3 2.557E-2
1.710E-1
7.245E-1
 1 5
26 GO:0045991 carbon catabolite activation of transcription 1.610E-3 2.557E-2
1.710E-1
7.245E-1
 1 5
27 GO:0031668 cellular response to extracellular stimulus 1.877E-3 2.557E-2
1.710E-1
8.448E-1
 2 212
28 GO:0010918 positive regulation of mitochondrial membrane potential 1.932E-3 2.557E-2
1.710E-1
8.693E-1
 1 6
29 GO:0045990 carbon catabolite regulation of transcription 1.932E-3 2.557E-2
1.710E-1
8.693E-1
 1 6
30 GO:1901857 positive regulation of cellular respiration 1.932E-3 2.557E-2
1.710E-1
8.693E-1
 1 6
31 GO:0046015 regulation of transcription by glucose 1.932E-3 2.557E-2
1.710E-1
8.693E-1
 1 6
32 GO:0045656 negative regulation of monocyte differentiation 1.932E-3 2.557E-2
1.710E-1
8.693E-1
 1 6
33 GO:0019087 transformation of host cell by virus 1.932E-3 2.557E-2
1.710E-1
8.693E-1
 1 6
34 GO:0044336 canonical Wnt signaling pathway involved in negative regulation of apoptotic process 1.932E-3 2.557E-2
1.710E-1
8.693E-1
 1 6
35 GO:0006006 glucose metabolic process 2.186E-3 2.669E-2
1.785E-1
9.837E-1
 2 229
36 GO:1903862 positive regulation of oxidative phosphorylation 2.253E-3 2.669E-2
1.785E-1
1.000E0
 1 7
37 GO:2000676 positive regulation of type B pancreatic cell apoptotic process 2.253E-3 2.669E-2
1.785E-1
1.000E0
 1 7
38 GO:2001171 positive regulation of ATP biosynthetic process 2.253E-3 2.669E-2
1.785E-1
1.000E0
 1 7
39 GO:1901724 positive regulation of cell proliferation involved in kidney development 2.575E-3 2.971E-2
1.987E-1
1.000E0
 1 8
40 GO:0042593 glucose homeostasis 2.807E-3 3.024E-2
2.023E-1
1.000E0
 2 260
41 GO:0033500 carbohydrate homeostasis 2.807E-3 3.024E-2
2.023E-1
1.000E0
 2 260
42 GO:2001169 regulation of ATP biosynthetic process 2.897E-3 3.024E-2
2.023E-1
1.000E0
 1 9
43 GO:0032868 response to insulin 2.935E-3 3.024E-2
2.023E-1
1.000E0
 2 266
44 GO:0019318 hexose metabolic process 2.957E-3 3.024E-2
2.023E-1
1.000E0
 2 267
45 GO:0021785 branchiomotor neuron axon guidance 3.218E-3 3.148E-2
2.105E-1
1.000E0
 1 10
46 GO:0051918 negative regulation of fibrinolysis 3.218E-3 3.148E-2
2.105E-1
1.000E0
 1 10
47 GO:0071496 cellular response to external stimulus 3.478E-3 3.192E-2
2.135E-1
1.000E0
 2 290
48 GO:0072203 cell proliferation involved in metanephros development 3.539E-3 3.192E-2
2.135E-1
1.000E0
 1 11
49 GO:1902237 positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway 3.539E-3 3.192E-2
2.135E-1
1.000E0
 1 11
50 GO:0097193 intrinsic apoptotic signaling pathway 3.741E-3 3.192E-2
2.135E-1
1.000E0
 2 301
Show 45 more annotations

3: GO: Cellular Component [Display Chart] 6 input genes in category / 21 annotations before applied cutoff / 19061 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0016604 nuclear body 1.904E-6 3.998E-5 1.457E-4 3.998E-5 4 364
2 GO:0016607 nuclear speck 1.614E-3 1.695E-2
6.178E-2
 3.390E-2 2 201
3 GO:0044665 MLL1/2 complex 8.783E-3 3.951E-2
1.440E-1
1.844E-1
 1 28
4 GO:0071339 MLL1 complex 8.783E-3 3.951E-2
1.440E-1
1.844E-1
 1 28
5 GO:0005719 nuclear euchromatin 9.408E-3 3.951E-2
1.440E-1
1.976E-1
 1 30
6 GO:0000791 euchromatin 1.253E-2 4.384E-2
1.598E-1
2.631E-1
 1 40
Show 1 more annotation

4: Human Phenotype [Display Chart] 3 input genes in category / 471 annotations before applied cutoff / 4707 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 HP:0011979 Elevated urinary dopamine 3.244E-5 8.059E-3
5.426E-2
 1.528E-2 2 16
2 HP:0011281 Abnormality of urine catecholamine concentration 5.133E-5 8.059E-3
5.426E-2
 2.418E-2 2 20
3 HP:0011976 Elevated urinary catecholamines 5.133E-5 8.059E-3
5.426E-2
 2.418E-2 2 20
4 HP:0006747 Ganglioneuroblastoma 7.453E-5 8.775E-3
5.909E-2
 3.510E-2 2 24
5 HP:0030450 Neuroplasm of the autonomic nervous system 1.997E-4 1.567E-2
1.055E-1
9.404E-2
 2 39
6 HP:0003005 Ganglioneuroma 1.997E-4 1.567E-2
1.055E-1
9.404E-2
 2 39
7 HP:0007379 Neoplasm of the genitourinary tract 3.203E-4 2.155E-2
1.451E-1
1.509E-1
 3 323
8 HP:0030080 Burkitt lymphoma 6.373E-4 3.752E-2
2.527E-1
3.002E-1
 1 1
9 HP:0003074 Hyperglycemia 8.254E-4 3.987E-2
2.684E-1
3.888E-1
 2 79
10 HP:0001954 Episodic fever 8.465E-4 3.987E-2
2.684E-1
3.987E-1
 2 80
11 HP:0100787 Prostate neoplasm 1.024E-3 4.144E-2
2.790E-1
4.824E-1
 2 88
12 HP:0002890 Thyroid carcinoma 1.119E-3 4.144E-2
2.790E-1
5.272E-1
 2 92
13 HP:0003072 Hypercalcemia 1.144E-3 4.144E-2
2.790E-1
5.387E-1
 2 93
14 HP:0004812 B Acute Lymphoblastic Leukemia 1.274E-3 4.288E-2
2.887E-1
6.003E-1
 1 2
15 HP:0100031 Neoplasm of the thyroid gland 1.402E-3 4.404E-2
2.965E-1
6.606E-1
 2 103
Show 10 more annotations

5: Mouse Phenotype [Display Chart] 6 input genes in category / 384 annotations before applied cutoff / 10355 genes in category

No results to display

6: Domain [Display Chart] 6 input genes in category / 54 annotations before applied cutoff / 18735 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 4.10.280.10 - Gene3D 3.783E-6 5.322E-5 2.435E-4 2.043E-4 3 109
2 PF00010 HLH Pfam 4.106E-6 5.322E-5 2.435E-4 2.217E-4 3 112
3 SM00353 HLH SMART 4.683E-6 5.322E-5 2.435E-4 2.529E-4 3 117
4 PS50888 BHLH PROSITE 4.805E-6 5.322E-5 2.435E-4 2.594E-4 3 118
5 IPR011598 bHLH dom InterPro 4.928E-6 5.322E-5 2.435E-4 2.661E-4 3 119
6 PF02344 Myc-LZ Pfam 3.203E-4 1.922E-3 8.792E-3 1.729E-2 1 1
7 IPR003646 SH3-like bac-type InterPro 3.203E-4 1.922E-3 8.792E-3 1.729E-2 1 1
8 IPR003327 Myc-LZ InterPro 3.203E-4 1.922E-3 8.792E-3 1.729E-2 1 1
9 PF08239 SH3 3 Pfam 3.203E-4 1.922E-3 8.792E-3 1.729E-2 1 1
10 IPR028118 Chibby fam InterPro 9.605E-4 4.715E-3 2.157E-2
5.187E-2
 1 3
11 PF14645 Chibby Pfam 9.605E-4 4.715E-3 2.157E-2
5.187E-2
 1 3
12 IPR012682 Tscrpt reg Myc N InterPro 1.281E-3 4.939E-3 2.260E-2
6.915E-2
 1 4
13 PF01056 Myc N Pfam 1.281E-3 4.939E-3 2.260E-2
6.915E-2
 1 4
14 IPR002418 Tscrpt reg Myc InterPro 1.281E-3 4.939E-3 2.260E-2
6.915E-2
 1 4
15 IPR012983 PHR InterPro 1.600E-3 5.401E-3 2.471E-2
8.642E-2
 1 5
16 PF08005 PHR Pfam 1.600E-3 5.401E-3 2.471E-2
8.642E-2
 1 5
17 PS51284 DOC PROSITE 2.240E-3 6.048E-3 2.767E-2
1.210E-1
 1 7
18 IPR004939 APC su10/DOC dom InterPro 2.240E-3 6.048E-3 2.767E-2
1.210E-1
 1 7
19 PF03256 ANAPC10 Pfam 2.240E-3 6.048E-3 2.767E-2
1.210E-1
 1 7
20 SM01337 APC10 SMART 2.240E-3 6.048E-3 2.767E-2
1.210E-1
 1 7
21 IPR001298 Filamin/ABP280 rpt InterPro 3.518E-3 7.401E-3 3.386E-2
1.900E-1
 1 11
22 IPR017868 Filamin/ABP280 repeat-like InterPro 3.518E-3 7.401E-3 3.386E-2
1.900E-1
 1 11
23 PF00630 Filamin Pfam 3.518E-3 7.401E-3 3.386E-2
1.900E-1
 1 11
24 PS50194 FILAMIN REPEAT PROSITE 3.518E-3 7.401E-3 3.386E-2
1.900E-1
 1 11
25 PS50144 MATH PROSITE 3.837E-3 7.401E-3 3.386E-2
2.072E-1
 1 12
26 PF00917 MATH Pfam 3.837E-3 7.401E-3 3.386E-2
2.072E-1
 1 12
27 SM00061 MATH SMART 3.837E-3 7.401E-3 3.386E-2
2.072E-1
 1 12
28 IPR002083 MATH/TRAF dom InterPro 3.837E-3 7.401E-3 3.386E-2
2.072E-1
 1 12
29 2.60.210.10 - Gene3D 4.476E-3 8.334E-3 3.813E-2
2.417E-1
 1 14
30 PF00415 RCC1 Pfam 6.389E-3 1.084E-2 4.960E-2
3.450E-1
 1 20
31 PS00625 RCC1 1 PROSITE 6.707E-3 1.084E-2 4.960E-2
3.622E-1
 1 21
32 PS00626 RCC1 2 PROSITE 6.707E-3 1.084E-2 4.960E-2
3.622E-1
 1 21
33 PS50012 RCC1 3 PROSITE 6.707E-3 1.084E-2 4.960E-2
3.622E-1
 1 21
34 IPR000408 Reg chr condens InterPro 7.026E-3 1.084E-2 4.960E-2
3.794E-1
 1 22
35 2.130.10.30 - Gene3D 7.026E-3 1.084E-2 4.960E-2
3.794E-1
 1 22
36 IPR009091 RCC1/BLIP-II InterPro 7.344E-3 1.102E-2
5.040E-2
3.966E-1
 1 23
37 IPR008974 TRAF-like InterPro 7.663E-3 1.118E-2
5.117E-2
4.138E-1
 1 24
38 PF13639 zf-RING 2 Pfam 1.654E-2 2.350E-2
1.075E-1
8.932E-1
 1 52
39 2.60.120.260 - Gene3D 2.316E-2 3.206E-2
1.467E-1
1.000E0
 1 73
40 PS50119 ZF BBOX PROSITE 2.535E-2 3.380E-2
1.547E-1
1.000E0
 1 80
41 IPR000315 Znf B-box InterPro 2.567E-2 3.380E-2
1.547E-1
1.000E0
 1 81
42 IPR008979 Galactose-bd-like InterPro 2.973E-2 3.823E-2
1.749E-1
1.000E0
 1 94
43 IPR014756 Ig E-set InterPro 3.285E-2 4.126E-2
1.888E-1
1.000E0
 1 104
Show 38 more annotations

7: Pathway [Display Chart] 5 input genes in category / 102 annotations before applied cutoff / 12450 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 169344 C-MYC pathway BioSystems: Pathway Interaction Database 2.971E-5 3.031E-3 1.578E-2 3.031E-3 2 22
2 M862 p38 MAPK Signaling Pathway MSigDB C2 BIOCARTA (v6.0) 1.000E-4 4.048E-3 2.108E-2 1.020E-2 2 40
3 P00046 Oxidative stress response PantherDB 1.326E-4 4.048E-3 2.108E-2 1.353E-2 2 46
4 169353 Validated targets of C-MYC transcriptional repression BioSystems: Pathway Interaction Database 2.339E-4 4.048E-3 2.108E-2 2.386E-2 2 61
5 137987 Regulation of Telomerase BioSystems: Pathway Interaction Database 2.740E-4 4.048E-3 2.108E-2 2.794E-2 2 66
6 1269778 Cyclin A:Cdk2-associated events at S phase entry BioSystems: REACTOME 3.353E-4 4.048E-3 2.108E-2 3.420E-2 2 73
7 1269769 Cyclin E associated events during G1/S transition BioSystems: REACTOME 3.445E-4 4.048E-3 2.108E-2 3.514E-2 2 74
8 137963 Regulation of nuclear SMAD2/3 signaling BioSystems: Pathway Interaction Database 3.730E-4 4.048E-3 2.108E-2 3.805E-2 2 77
9 169352 Regulation of Wnt-mediated beta catenin signaling and target gene transcription BioSystems: Pathway Interaction Database 3.927E-4 4.048E-3 2.108E-2 4.005E-2 2 79
10 169351 Validated targets of C-MYC transcriptional activation BioSystems: Pathway Interaction Database 4.128E-4 4.048E-3 2.108E-2 4.211E-2 2 81
11 83118 Small cell lung cancer BioSystems: KEGG 4.439E-4 4.048E-3 2.108E-2 4.528E-2 2 84
12 M13863 MAPKinase Signaling Pathway MSigDB C2 BIOCARTA (v6.0) 4.762E-4 4.048E-3 2.108E-2 4.857E-2 2 87
13 1269768 G1/S Transition BioSystems: REACTOME 9.190E-4 7.211E-3 3.755E-2
9.374E-2
 2 121
14 1269777 S Phase BioSystems: REACTOME 1.093E-3 7.960E-3 4.145E-2
1.114E-1
 2 132
15 1269764 Mitotic G1-G1/S phases BioSystems: REACTOME 1.316E-3 8.952E-3 4.661E-2
1.343E-1
 2 145
16 1427843 TFAP2 (AP-2) family regulates transcription of cell cycle factors BioSystems: REACTOME 2.007E-3 1.212E-2
6.311E-2
2.047E-1
 1 5
17 523016 Transcriptional misregulation in cancer BioSystems: KEGG 2.020E-3 1.212E-2
6.311E-2
2.060E-1
 2 180
18 1269603 Binding of TCF/LEF:CTNNB1 to target gene promoters BioSystems: REACTOME 2.809E-3 1.592E-2
8.287E-2
2.865E-1
 1 7
19 1269599 TCF dependent signaling in response to WNT BioSystems: REACTOME 3.620E-3 1.943E-2
1.012E-1
3.692E-1
 2 242
20 83048 MAPK signaling pathway BioSystems: KEGG 4.012E-3 2.046E-2
1.065E-1
4.092E-1
 2 255
21 M4388 Cadmium induces DNA synthesis and proliferation in macrophages MSigDB C2 BIOCARTA (v6.0) 6.410E-3 2.941E-2
1.532E-1
6.538E-1
 1 16
22 M11358 Tumor Suppressor Arf Inhibits Ribosomal Biogenesis MSigDB C2 BIOCARTA (v6.0) 6.810E-3 2.941E-2
1.532E-1
6.946E-1
 1 17
23 1269594 Signaling by Wnt BioSystems: REACTOME 7.041E-3 2.941E-2
1.532E-1
7.182E-1
 2 340
24 M10401 Telomeres, Telomerase, Cellular Aging, and Immortality MSigDB C2 BIOCARTA (v6.0) 7.209E-3 2.941E-2
1.532E-1
7.353E-1
 1 18
25 M7552 Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy MSigDB C2 BIOCARTA (v6.0) 7.209E-3 2.941E-2
1.532E-1
7.353E-1
 1 18
26 M11420 CTCF: First Multivalent Nuclear Factor MSigDB C2 BIOCARTA (v6.0) 9.204E-3 3.432E-2
1.787E-1
9.388E-1
 1 23
27 M7897 Inhibition of Cellular Proliferation by Gleevec MSigDB C2 BIOCARTA (v6.0) 9.204E-3 3.432E-2
1.787E-1
9.388E-1
 1 23
28 83105 Pathways in cancer BioSystems: KEGG 9.422E-3 3.432E-2
1.787E-1
9.611E-1
 2 395
29 M16517 WNT Signaling Pathway MSigDB C2 BIOCARTA (v6.0) 1.040E-2 3.598E-2
1.873E-1
1.000E0
 1 26
30 M17941 Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells MSigDB C2 BIOCARTA (v6.0) 1.080E-2 3.598E-2
1.873E-1
1.000E0
 1 27
31 M287 Erk1/Erk2 Mapk Signaling pathway MSigDB C2 BIOCARTA (v6.0) 1.120E-2 3.598E-2
1.873E-1
1.000E0
 1 28
32 83112 Thyroid cancer BioSystems: KEGG 1.159E-2 3.598E-2
1.873E-1
1.000E0
 1 29
33 138061 CD40/CD40L signaling BioSystems: Pathway Interaction Database 1.199E-2 3.598E-2
1.873E-1
1.000E0
 1 30
34 137988 IL2 signaling events mediated by STAT5 BioSystems: Pathway Interaction Database 1.199E-2 3.598E-2
1.873E-1
1.000E0
 1 30
35 1269528 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription BioSystems: REACTOME 1.358E-2 3.737E-2
1.946E-1
1.000E0
 1 34
36 M17761 Wnt/beta-catenin Pathway MSigDB C2 BIOCARTA (v6.0) 1.358E-2 3.737E-2
1.946E-1
1.000E0
 1 34
37 138012 Signaling mediated by p38-alpha and p38-beta BioSystems: Pathway Interaction Database 1.398E-2 3.737E-2
1.946E-1
1.000E0
 1 35
38 137935 FOXM1 transcription factor network BioSystems: Pathway Interaction Database 1.477E-2 3.737E-2
1.946E-1
1.000E0
 1 37
39 137938 IL2 signaling events mediated by PI3K BioSystems: Pathway Interaction Database 1.477E-2 3.737E-2
1.946E-1
1.000E0
 1 37
40 M8615 IL-2 Receptor Beta Chain in T cell Activation MSigDB C2 BIOCARTA (v6.0) 1.517E-2 3.737E-2
1.946E-1
1.000E0
 1 38
41 1427839 Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors BioSystems: REACTOME 1.596E-2 3.737E-2
1.946E-1
1.000E0
 1 40
42 83115 Bladder cancer BioSystems: KEGG 1.636E-2 3.737E-2
1.946E-1
1.000E0
 1 41
43 137957 LKB1 signaling events BioSystems: Pathway Interaction Database 1.676E-2 3.737E-2
1.946E-1
1.000E0
 1 42
44 137932 IL6-mediated signaling events BioSystems: Pathway Interaction Database 1.715E-2 3.737E-2
1.946E-1
1.000E0
 1 43
45 1269604 Deactivation of the beta-catenin transactivating complex BioSystems: REACTOME 1.715E-2 3.737E-2
1.946E-1
1.000E0
 1 43
46 137912 Hedgehog signaling events mediated by Gli proteins BioSystems: Pathway Interaction Database 1.755E-2 3.737E-2
1.946E-1
1.000E0
 1 44
47 138023 Ceramide signaling pathway BioSystems: Pathway Interaction Database 1.755E-2 3.737E-2
1.946E-1
1.000E0
 1 44
48 P04398 p53 pathway feedback loops 2 PantherDB 1.794E-2 3.737E-2
1.946E-1
1.000E0
 1 45
49 137914 Presenilin action in Notch and Wnt signaling BioSystems: Pathway Interaction Database 1.834E-2 3.737E-2
1.946E-1
1.000E0
 1 46
50 1269527 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer BioSystems: REACTOME 1.834E-2 3.737E-2
1.946E-1
1.000E0
 1 46
Show 45 more annotations

8: Pubmed [Display Chart] 6 input genes in category / 3312 annotations before applied cutoff / 38193 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 15358760 Sterol-responsive element-binding protein (SREBP) 2 down-regulates ATP-binding cassette transporter A1 in vascular endothelial cells: a novel role of SREBP in regulating cholesterol metabolism. Pubmed 1.206E-10 3.994E-7 3.468E-6 3.994E-7 3 8
2 19623651 Prostaglandin E(2) promotes cell proliferation via protein kinase C/extracellular signal regulated kinase pathway-dependent induction of c-Myc expression in human esophageal squamous cell carcinoma cells. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
3 7860774 Cell density and paradoxical transcriptional properties of c-Myc and Max in cultured mouse fibroblasts. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
4 18620061 Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
5 16201965 Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
6 17072308 Direct observation of individual endogenous protein complexes in situ by proximity ligation. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
7 23816886 MYC degradation under low O2 tension promotes survival by evading hypoxia-induced cell death. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
8 9680483 Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
9 16606833 Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
10 9689053 Identification of a large Myc-binding protein that contains RCC1-like repeats. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
11 24657798 Small-molecule inhibitors of the Myc oncoprotein. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
12 25522242 Identification of c-MYC SUMOylation by mass spectrometry. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
13 26474287 Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
14 23592794 MYC/MAX control ERK signaling and pluripotency by regulation of dual-specificity phosphatases 2 and 7. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
15 9764821 The C. elegans MDL-1 and MXL-1 proteins can functionally substitute for vertebrate MAD and MAX. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
16 28414305 SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
17 1730411 Myc and Max associate in vivo. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
18 22733550 New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
19 28719624 Sequence-specific DNA binding by MYC/MAX to low-affinity non-E-box motifs. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
20 25875098 Reversible linkage of two distinct small molecule inhibitors of Myc generates a dimeric inhibitor with improved potency that is active in myc over-expressing cancer cell lines. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
21 29695509 Myc phosphorylation in its basic helix-loop-helix region destabilizes transient α-helical structures, disrupting Max and DNA binding. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
22 22384171 The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities. Pubmed 2.057E-8 3.096E-6 2.688E-5 6.812E-5 2 2
23 24731854 The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
24 24857747 Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
25 10319872 c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
26 25284584 USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
27 12553908 X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
28 24951594 Sin3b interacts with Myc and decreases Myc levels. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
29 16596619 Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
30 27859590 Miz-1 and Max compete to engage c-Myc: implication for the mechanism of inhibition of c-Myc transcriptional activity by Miz-1. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
31 8224841 A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
32 16705173 A conserved Myc protein domain, MBIV, regulates DNA binding, apoptosis, transformation, and G2 arrest. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
33 7478599 c-Myc and Max transregulate the mouse ornithine decarboxylase promoter through interaction with two downstream CACGTG motifs. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
34 16140957 Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
35 16352593 Targeting of Miz-1 is essential for Myc-mediated apoptosis. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
36 26517351 Clinical significance of high c-MYC and low MYCBP2 expression and their association with Ikaros dysfunction in adult acute lymphoblastic leukemia. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
37 14749374 Negative control of the Myc protein by the stress-responsive kinase Pak2. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
38 12706874 Yaf2 inhibits Myc biological function. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
39 10465786 The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
40 21807113 Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
41 19578763 hnRNP U interacts with the c-Myc-Max complex on the E-box promoter region inducing the ornithine decarboxylase gene. Pubmed 6.170E-8 4.984E-6 4.327E-5 2.043E-4 2 3
42 2006410 Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
43 12821782 Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
44 9708738 The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
45 20434984 c-Myc regulates transcriptional pause release. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
46 7479755 Myc and Max: molecular evolution of a family of proto-oncogene products and their dimerization partner. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
47 20426839 Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
48 26267534 Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
49 15642350 Acquisition of essential somatic cell cycle regulatory protein expression and implied activity occurs at the second to third cell division in mouse preimplantation embryos. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
50 12824180 Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression. Pubmed 1.234E-7 7.567E-6 6.571E-5 4.086E-4 2 4
Show 45 more annotations

9: Interaction [Display Chart] 6 input genes in category / 1217 annotations before applied cutoff / 17703 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 int:TRRAP TRRAP interactions 7.268E-6 3.988E-3 3.063E-2 8.845E-3 3 128
2 int:SMARCA5 SMARCA5 interactions 1.194E-5 3.988E-3 3.063E-2 1.453E-2 3 151
3 int:MNT MNT interactions 1.299E-5 3.988E-3 3.063E-2 1.581E-2 2 17
4 int:PI4KB PI4KB interactions 1.814E-5 3.988E-3 3.063E-2 2.208E-2 2 20
5 int:MAX MAX interactions 2.124E-5 3.988E-3 3.063E-2 2.585E-2 3 183
6 int:DYNC1H1 DYNC1H1 interactions 2.230E-5 3.988E-3 3.063E-2 2.714E-2 3 186
7 int:ROBO2 ROBO2 interactions 2.862E-5 3.988E-3 3.063E-2 3.483E-2 2 25
8 int:WDR5 WDR5 interactions 3.206E-5 3.988E-3 3.063E-2 3.901E-2 3 210
9 int:LRCH2 LRCH2 interactions 3.348E-5 3.988E-3 3.063E-2 4.074E-2 2 27
10 int:EPC2 EPC2 interactions 3.604E-5 3.988E-3 3.063E-2 4.387E-2 2 28
11 int:MXI1 MXI1 interactions 3.604E-5 3.988E-3 3.063E-2 4.387E-2 2 28
12 int:BRD3 BRD3 interactions 5.031E-5 4.356E-3 3.347E-2
6.123E-2
 2 33
13 int:KIF21B KIF21B interactions 5.668E-5 4.356E-3 3.347E-2
6.898E-2
 2 35
14 int:FOSL1 FOSL1 interactions 6.000E-5 4.356E-3 3.347E-2
7.302E-2
 2 36
15 int:SKP1 SKP1 interactions 6.488E-5 4.356E-3 3.347E-2
7.896E-2
 3 266
16 int:UBN1 UBN1 interactions 6.693E-5 4.356E-3 3.347E-2
8.146E-2
 2 38
17 int:FOXR2 FOXR2 interactions 6.693E-5 4.356E-3 3.347E-2
8.146E-2
 2 38
18 int:MYCN MYCN interactions 7.424E-5 4.356E-3 3.347E-2
9.035E-2
 2 40
19 int:MCAT MCAT interactions 7.424E-5 4.356E-3 3.347E-2
9.035E-2
 2 40
20 int:FOXR1 FOXR1 interactions 7.804E-5 4.356E-3 3.347E-2
9.497E-2
 2 41
21 int:ZBTB17 ZBTB17 interactions 8.193E-5 4.356E-3 3.347E-2
9.971E-2
 2 42
22 int:EPC1 EPC1 interactions 8.193E-5 4.356E-3 3.347E-2
9.971E-2
 2 42
23 int:MXD1 MXD1 interactions 8.591E-5 4.356E-3 3.347E-2
1.046E-1
 2 43
24 int:BRD8 BRD8 interactions 8.591E-5 4.356E-3 3.347E-2
1.046E-1
 2 43
25 int:CLASP1 CLASP1 interactions 8.999E-5 4.381E-3 3.365E-2
1.095E-1
 2 44
26 int:SMARCA1 SMARCA1 interactions 1.028E-4 4.811E-3 3.696E-2
1.251E-1
 2 47
27 int:IGF2R IGF2R interactions 1.118E-4 5.039E-3 3.871E-2
1.360E-1
 2 49
28 int:PIM1 PIM1 interactions 1.309E-4 5.499E-3 4.225E-2
1.593E-1
 2 53
29 int:FBXW7 FBXW7 interactions 1.310E-4 5.499E-3 4.225E-2
1.595E-1
 3 337
30 int:SAP130 SAP130 interactions 1.359E-4 5.514E-3 4.236E-2
1.654E-1
 2 54
31 int:PPP1CA PPP1CA interactions 1.728E-4 6.785E-3
5.212E-2
2.103E-1
 3 370
32 int:HDAC2 HDAC2 interactions 1.841E-4 7.003E-3
5.379E-2
2.241E-1
 3 378
33 int:EP400 EP400 interactions 1.912E-4 7.051E-3
5.417E-2
2.327E-1
 2 64
34 int:CAPRIN1 CAPRIN1 interactions 1.972E-4 7.060E-3
5.423E-2
2.400E-1
 2 65
35 int:PLEKHF2 PLEKHF2 interactions 2.159E-4 7.102E-3
5.455E-2
2.628E-1
 2 68
36 int:PKN1 PKN1 interactions 2.159E-4 7.102E-3
5.455E-2
2.628E-1
 2 68
37 int:CDK12 CDK12 interactions 2.159E-4 7.102E-3
5.455E-2
2.628E-1
 2 68
38 int:USF1 USF1 interactions 2.223E-4 7.120E-3
5.470E-2
2.706E-1
 2 69
39 int:DMAP1 DMAP1 interactions 2.421E-4 7.555E-3
5.804E-2
2.947E-1
 2 72
40 int:ARHGEF2 ARHGEF2 interactions 2.558E-4 7.782E-3
5.978E-2
3.113E-1
 2 74
41 int:SH3BP4 SH3BP4 interactions 2.627E-4 7.799E-3
5.991E-2
3.198E-1
 2 75
42 int:PLIN3 PLIN3 interactions 2.698E-4 7.818E-3
6.006E-2
3.284E-1
 2 76
43 int:PHLDB2 PHLDB2 interactions 2.770E-4 7.839E-3
6.021E-2
3.371E-1
 2 77
44 int:FOXO3 FOXO3 interactions 2.842E-4 7.861E-3
6.039E-2
3.459E-1
 2 78
45 int:TFAP2A TFAP2A interactions 2.990E-4 7.972E-3
6.124E-2
3.638E-1
 2 80
46 int:HIRA HIRA interactions 3.218E-4 7.972E-3
6.124E-2
3.917E-1
 2 83
47 int:TIAM1 TIAM1 interactions 3.296E-4 7.972E-3
6.124E-2
4.011E-1
 2 84
48 int:ABLIM1 ABLIM1 interactions 3.296E-4 7.972E-3
6.124E-2
4.011E-1
 2 84
49 int:DCLK1 DCLK1 interactions 3.375E-4 7.972E-3
6.124E-2
4.107E-1
 2 85
50 int:WEE1 WEE1 interactions 3.375E-4 7.972E-3
6.124E-2
4.107E-1
 2 85
Show 45 more annotations

10: Cytoband [Display Chart] 6 input genes in category / 6 annotations before applied cutoff / 34661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 14q23 14q23 1.557E-3 3.320E-3 8.134E-3 9.342E-3 1 9
2 13q22 13q22 1.903E-3 3.320E-3 8.134E-3 1.142E-2 1 11
3 1q22-q23 1q22-q23 2.248E-3 3.320E-3 8.134E-3 1.349E-2 1 13
4 22q12 22q12 2.594E-3 3.320E-3 8.134E-3 1.556E-2 1 15
5 8q24.21 8q24.21 2.767E-3 3.320E-3 8.134E-3 1.660E-2 1 16
6 17q21.33 17q21.33 7.249E-3 7.249E-3 1.776E-2 4.349E-2 1 42
Show 1 more annotation

11: Transcription Factor Binding Site [Display Chart] 4 input genes in category / 68 annotations before applied cutoff / 9770 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 V$HIF1 Q3 V$HIF1 Q3 2.042E-3 4.473E-2
2.149E-1
1.389E-1
 2 183
2 V$MYOD Q6 V$MYOD Q6 2.435E-3 4.473E-2
2.149E-1
1.656E-1
 2 200
3 V$AP2 Q3 V$AP2 Q3 2.606E-3 4.473E-2
2.149E-1
1.772E-1
 2 207
4 V$AP4 Q6 01 V$AP4 Q6 01 2.631E-3 4.473E-2
2.149E-1
1.789E-1
 2 208

12: Gene Family [Display Chart] 4 input genes in category / 2 annotations before applied cutoff / 18194 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 420 Basic helix-loop-helix proteins genenames.org 8.564E-7 1.713E-6 2.569E-6 1.713E-6 3 110
2 861 Kelch like|BTB domain containing genenames.org 2.914E-2 2.914E-2 4.371E-2
5.828E-2
 1 134

13: Coexpression [Display Chart] 6 input genes in category / 992 annotations before applied cutoff / 23137 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 M5819 Genes up-regulated in comparison of naive CD8 T cells versus effector CD8 T cells. MSigDB C7: Immunologic Signatures (v6.0) 1.248E-5 1.238E-2
9.260E-2
 1.238E-2 3 200
2 M1885 Genes down-regulated in vascular smooth muscle cells (VSMC) by MAPK8 (JNK1) [GeneID=5599]. MSigDB C2: CGP Curated Gene Sets (v6.0) 7.579E-5 2.184E-2
1.633E-1
7.519E-2
 3 366
3 14749762-Table2 Human Leukemia Staber04 58genes GeneSigDB 7.678E-5 2.184E-2
1.633E-1
7.616E-2
 2 53
4 M13522 Common down-regulated transcripts in fibroblasts expressing either XP/CS or TDD mutant forms of ERCC3 [GeneID=2071], after UVC irradiation. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.725E-4 2.184E-2
1.633E-1
1.712E-1
 3 483
5 M1852 Down-regulated genes that best disciminate plasmablastic plasmacytoma from plasmacytic plasmacytoma tumors. MSigDB C2: CGP Curated Gene Sets (v6.0) 2.743E-4 2.184E-2
1.633E-1
2.721E-1
 2 100
6 M7484 Genes down-regulated in SCC12B2 cells (squamous cell carcinoma) by UV-B irradiation. MSigDB C2: CGP Curated Gene Sets (v6.0) 4.147E-4 2.184E-2
1.633E-1
4.113E-1
 2 123
7 M5942 Genes down-regulated in response to ultraviolet (UV) radiation. MSigDB H: Hallmark Gene Sets (v6.0) 5.676E-4 2.184E-2
1.633E-1
5.631E-1
 2 144
8 M8512 Genes up-regulated in TK6, WTK1, and NH32 cell lines (lymphoblast) in response to ionizing radiation. MSigDB C2: CGP Curated Gene Sets (v6.0) 6.075E-4 2.184E-2
1.633E-1
6.027E-1
 2 149
9 M8129 Genes down-regulated in AGS cells (gastric adenocarcinoma): control versus H. pylori LPS. MSigDB C7: Immunologic Signatures (v6.0) 7.175E-4 2.184E-2
1.633E-1
7.117E-1
 2 162
10 M7007 Genes down-regulated in hematopoietic stem cells versus megakaryo-erythrocyte progenitors. MSigDB C7: Immunologic Signatures (v6.0) 7.531E-4 2.184E-2
1.633E-1
7.471E-1
 2 166
11 M8186 Genes up-regulated in B lymphocytes after immunization with: monophosphoryl lipid A versus imiquimod [PubChem=13982876]. MSigDB C7: Immunologic Signatures (v6.0) 7.989E-4 2.184E-2
1.633E-1
7.925E-1
 2 171
12 M2670 Genes down-regulated by everolimus [PubChem = 6442177] in prostate tissue. MSigDB C6: Oncogenic Signatures (v6.0) 9.239E-4 2.184E-2
1.633E-1
9.165E-1
 2 184
13 M2771 Genes down-regulated during late stages of differentiation of embryoid bodies from V6.5 embryonic stem cells. MSigDB C6: Oncogenic Signatures (v6.0) 9.440E-4 2.184E-2
1.633E-1
9.364E-1
 2 186
14 M6525 Genes down-regulated in epithelial cells (24h): untreated versus interferon alpha. MSigDB C7: Immunologic Signatures (v6.0) 1.016E-3 2.184E-2
1.633E-1
1.000E0
 2 193
15 M9245 Genes up-regulated in dendritic cells: untreated versus hydrogen peroxide [PubChem=784]. MSigDB C7: Immunologic Signatures (v6.0) 1.037E-3 2.184E-2
1.633E-1
1.000E0
 2 195
16 M4958 Genes up-regulated in comparison of B cells from influenza vaccinee at day 7 post-vaccination versus plasmacytoid dendritic cells (pDC) at day 7 post-vaccination. MSigDB C7: Immunologic Signatures (v6.0) 1.047E-3 2.184E-2
1.633E-1
1.000E0
 2 196
17 M4940 Genes up-regulated in comparison of B cells versus plasmacytoid dendritic cells (pDC) . MSigDB C7: Immunologic Signatures (v6.0) 1.058E-3 2.184E-2
1.633E-1
1.000E0
 2 197
18 M3319 Genes up-regulated in comparison of resting CD4 [GeneID=920] T cells versus directly activated CD4 [GeneID=920] T cells. MSigDB C7: Immunologic Signatures (v6.0) 1.069E-3 2.184E-2
1.633E-1
1.000E0
 2 198
19 M6523 Genes down-regulated in epithelial cells (24h): untreated versus IFNG [GeneID=3458]. MSigDB C7: Immunologic Signatures (v6.0) 1.079E-3 2.184E-2
1.633E-1
1.000E0
 2 199
20 M3028 Genes down-regulated in comparison of naive versus memory CD8 T cells (day 40+ following LCMV-Armstrong infection). MSigDB C7: Immunologic Signatures (v6.0) 1.079E-3 2.184E-2
1.633E-1
1.000E0
 2 199
21 M8874 Genes down-regulated in common lymphoid progenitors versus RAG2 [GeneID=5897] knockout NK cells. MSigDB C7: Immunologic Signatures (v6.0) 1.079E-3 2.184E-2
1.633E-1
1.000E0
 2 199
22 M5295 Genes up-regulated in comparison of untreated CD4 [GeneID=920] memory T cells from old donors versus those treated with TSST at 16 h. MSigDB C7: Immunologic Signatures (v6.0) 1.079E-3 2.184E-2
1.633E-1
1.000E0
 2 199
23 M9360 Genes up-regulated in day 7 germinal center B cells versus day 7 plasma cells. MSigDB C7: Immunologic Signatures (v6.0) 1.079E-3 2.184E-2
1.633E-1
1.000E0
 2 199
24 M4237 Genes up-regulated in comparison of untreated CD4 [GeneID=920] T cells at 1 h versus the untreated cells at 72 h. MSigDB C7: Immunologic Signatures (v6.0) 1.079E-3 2.184E-2
1.633E-1
1.000E0
 2 199
25 M9616 Genes down-regulated in CD42 high [GeneID=100133941] cells from thymus: T reg versus T conv. MSigDB C7: Immunologic Signatures (v6.0) 1.079E-3 2.184E-2
1.633E-1
1.000E0
 2 199
26 M6033 Genes down-regulated in CD4 [GeneID=920] T cells activated by anti-CD3 and anti-CD28: IL-12 (48h) versus untreated (48h). MSigDB C7: Immunologic Signatures (v6.0) 1.079E-3 2.184E-2
1.633E-1
1.000E0
 2 199
27 M8628 Genes down-regulated in bone marrow-derived dendritic cells: low dose of 1,3-beta-D-oligoglucan [PubChem=11375554] versus CSF2 [GeneID=1437] and low dose of 1,3-beta-D-oligoglucan [PubChem=11375554]. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
28 M9301 Genes up-regulated in Lung dendritic cell from untreated IL-1R mice versus Lung dendritic cell from Ad5 inf IL-1R mice. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
29 M5991 Genes down-regulated in macrophages: wildtype versus SOCS3 [GeneID=9021]. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
30 M8644 Genes up-regulated in bone marrow-derived macrophages: wildtype versus NFAT5 [GeneID=10725] knockout. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
31 M9332 Genes down-regulated in day 7 germinal center B cells versus day 40 germinal center B cells. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
32 M9358 Genes up-regulated in day 7 memory B cells versus day 40 germinal center B cells. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
33 M6936 Genes up-regulated in B lymphocytes: CpG oligodeoxynucleotide 1826 versus PL2-3 (Chromatin IC). MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
34 M8079 Genes down-regulated in lymph node CD4 [GeneID=920] T cells: scurfy (non-functional form of FOXP3 [GeneID=50943]) versus scurfy and IL2 [GeneID=3558] knockout. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
35 M5837 Genes down-regulated in comparison of effector CD8 T cells versus memory CD8 T cells. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
36 M3012 Genes up-regulated in comparison of naive versus effector CD8 T cells at the peak expansion phase (day8 after LCMV-Armstrong infection). MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
37 M5268 Genes down-regulated in comparison of macrophages exposed to 5 worms/well B. malayi versus macrophages exposed to M. tuberculosis. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
38 M5997 Genes up-regulated in macrophages treated by IL6 [GeneID=3569]: 100min versus 400min. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
39 M8967 Genes down-regulated in CD4 [GeneID=920] over-expressing: FOXP3 [GeneID=50943] and PPARg1 form of PPARG [GeneID=5468] versus FOXP3 [GeneID=50943]. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
40 M9839 Genes down-regulated in CD40L and IL-2 IL-4 IL-5 stimulated at day 1 B cell IRF4high versus CD40L and IL-2 IL-4 IL-5 stimulated at day 3 B cell IRF4high. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
41 M6930 Genes up-regulated in B lymphocytes: anti IgM versus PL2-3 (Chromatin IC). MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
42 M303 Genes up-regulated in primary bronchial epithelial cells: control versus stimulated with IL17A and IL22 [GeneID=3605;50616]. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
43 M5324 Genes down-regulated in comparison of memory CD4 [GeneID=920] T cells from young donors treated with TSST at 72 h versus those from old donors treated with TSST at 72 h. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
44 M3073 Genes up-regulated in comparison of memory CD8 T cells versus effector CD8 T cells. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
45 M2720 Genes up-regulated in primary thyrocyte cultures in response to cAMP signaling pathway activation by thyrotropin (TSH). MSigDB C6: Oncogenic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
46 M6614 Genes down-regulated in bone marrow-derived macrophages (45 min): IL10 [GeneID=3486] and LPS versus IL6 [GeneID=3469] and LPS. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
47 M3832 Genes up-regulated in comparison of dendritic cells (DC) stimulated with poly(I:C) (TLR3 agonist) at 4 h versus DC cells stimulated with Pam3Csk4 (TLR1/2 agonist) at 4 h. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
48 M9846 Genes down-regulated in CD40L and IL-2 IL-4 IL-5 stimulated at day 3 B cell IRF4high versus CD40L and IL-2 IL-4 IL-5 stimulated at day 3 B cell IRF4intermediate. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
49 M3866 Genes down-regulated in comparison of dendritic cells (DC) stimulated with Pam3Csk4 (TLR1/2 agonist) at 8 h versus DC cells stimulated with CpG DNA (TLR9 agonist) at 8 h. MSigDB C7: Immunologic Signatures (v6.0) 1.090E-3 2.184E-2
1.633E-1
1.000E0
 2 200
50 M8445 Genes positively correlated with amplifications of MYC [GeneID=4609] in SCLC (small cell lung cancer) cell lines. MSigDB C2: CGP Curated Gene Sets (v6.0) 1.101E-3 2.184E-2
1.633E-1
1.000E0
 2 201
Show 45 more annotations

14: Coexpression Atlas [Display Chart] 6 input genes in category / 363 annotations before applied cutoff / 21829 genes in category

No results to display

15: Computational [Display Chart] 6 input genes in category / 51 annotations before applied cutoff / 10037 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 M19116 GCM MAX Neighborhood of MAX MSigDb: C4 - CGN: Cancer Gene Neighborhood (v6.0) 1.286E-4 6.558E-3 2.964E-2 6.558E-3 2 30

16: MicroRNA [Display Chart] 6 input genes in category / 379 annotations before applied cutoff / 72241 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 hsa-miR-4668-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.378E-6 1.280E-3 8.343E-3 1.280E-3 3 402
2 hsa-miR-599:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.495E-5 5.077E-3 3.308E-2 1.325E-2 2 111
3 hsa-miR-126-5p:Functional MTI Functional MTI miRTarbase 4.019E-5 5.077E-3 3.308E-2 1.523E-2 2 119
4 hsa-miR-320b:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.970E-5 5.656E-3 3.686E-2 2.263E-2 2 145
5 hsa-miR-1248:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.545E-5 5.719E-3 3.727E-2 2.859E-2 2 163
6 hsa-miR-148a-3p:Functional MTI Functional MTI miRTarbase 1.288E-4 7.112E-3 4.634E-2 4.881E-2 2 213
7 hsa-miR-338-3p:PITA hsa-miR-338-3p:PITA TOP PITA 1.337E-4 7.112E-3 4.634E-2
5.066E-2
 2 217
8 hsa-miR-4533:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.501E-4 7.112E-3 4.634E-2
5.690E-2
 2 230
9 hsa-miR-196a-5p:Functional MTI Functional MTI miRTarbase 2.601E-4 1.095E-2
7.137E-2
9.858E-2
 2 303
10 hsa-miR-768-3p:PITA hsa-miR-768-3p:PITA TOP PITA 3.646E-4 1.382E-2
9.003E-2
1.382E-1
 2 359
11 hsa-miR-130a-3p:Functional MTI Functional MTI miRTarbase 4.476E-4 1.542E-2
1.005E-1
1.696E-1
 2 398
12 TCGATGG,MIR-213:MSigDB TCGATGG,MIR-213:MSigDB MSigDB 4.982E-4 1.574E-2
1.025E-1
1.888E-1
 1 6
13 hsa-miR-1306:mirSVR lowEffct hsa-miR-1306:mirSVR nonconserved lowEffect-0.1-0.5 MicroRNA.org 6.044E-4 1.688E-2
1.100E-1
2.291E-1
 2 463
14 hsa-miR-375:Functional MTI Functional MTI miRTarbase 6.413E-4 1.688E-2
1.100E-1
2.430E-1
 2 477
15 hsa-miR-129-5p:PITA hsa-miR-129-5p:PITA TOP PITA 6.682E-4 1.688E-2
1.100E-1
2.532E-1
 2 487
16 hsa-miR-1247:PITA hsa-miR-1247:PITA TOP PITA 1.411E-3 3.014E-2
1.964E-1
5.348E-1
 1 17
17 hsa-miR-516a-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.494E-3 3.014E-2
1.964E-1
5.663E-1
 1 18
18 hsa-miR-8074:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.577E-3 3.014E-2
1.964E-1
5.977E-1
 1 19
19 hsa-miR-487b-3p:Functional MTI Functional MTI miRTarbase 1.660E-3 3.014E-2
1.964E-1
6.291E-1
 1 20
20 hsa-miR-6743-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.826E-3 3.014E-2
1.964E-1
6.920E-1
 1 22
21 hsa-miR-451a:Functional MTI Functional MTI miRTarbase 2.572E-3 3.014E-2
1.964E-1
9.748E-1
 1 31
22 hsa-miR-371a-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 2.655E-3 3.014E-2
1.964E-1
1.000E0
 1 32
23 hsa-miR-4759:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 2.655E-3 3.014E-2
1.964E-1
1.000E0
 1 32
24 hsa-miR-6755-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 2.738E-3 3.014E-2
1.964E-1
1.000E0
 1 33
25 hsa-miR-3117-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.152E-3 3.014E-2
1.964E-1
1.000E0
 1 38
26 hsa-miR-3907:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.566E-3 3.014E-2
1.964E-1
1.000E0
 1 43
27 hsa-miR-548q:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.063E-3 3.014E-2
1.964E-1
1.000E0
 1 49
28 hsa-miR-3169:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.146E-3 3.014E-2
1.964E-1
1.000E0
 1 50
29 hsa-miR-889-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.311E-3 3.014E-2
1.964E-1
1.000E0
 1 52
30 hsa-miR-4259:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.311E-3 3.014E-2
1.964E-1
1.000E0
 1 52
31 hsa-miR-609:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.311E-3 3.014E-2
1.964E-1
1.000E0
 1 52
32 hsa-miR-3912-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.394E-3 3.014E-2
1.964E-1
1.000E0
 1 53
33 hsa-miR-8083:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.394E-3 3.014E-2
1.964E-1
1.000E0
 1 53
34 hsa-miR-487a-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.477E-3 3.014E-2
1.964E-1
1.000E0
 1 54
35 hsa-miR-184:Functional MTI Functional MTI miRTarbase 4.560E-3 3.014E-2
1.964E-1
1.000E0
 1 55
36 hsa-miR-1244:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.890E-3 3.014E-2
1.964E-1
1.000E0
 1 59
37 hsa-miR-4752:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.139E-3 3.014E-2
1.964E-1
1.000E0
 1 62
38 hsa-miR-606:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.221E-3 3.014E-2
1.964E-1
1.000E0
 1 63
39 hsa-miR-129-2-3p:Functional MTI Functional MTI miRTarbase 5.883E-3 3.014E-2
1.964E-1
1.000E0
 1 71
40 hsa-miR-4503:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.883E-3 3.014E-2
1.964E-1
1.000E0
 1 71
41 hsa-miR-1470:mirSVR highEffct hsa-miR-1470:mirSVR nonconserved highEffect-0.5 MicroRNA.org 6.048E-3 3.014E-2
1.964E-1
1.000E0
 1 73
42 hsa-miR-1247:mirSVR highEffct hsa-miR-1247:mirSVR nonconserved highEffect-0.5 MicroRNA.org 6.048E-3 3.014E-2
1.964E-1
1.000E0
 1 73
43 hsa-miR-4289:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.048E-3 3.014E-2
1.964E-1
1.000E0
 1 73
44 hsa-miR-4677-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.131E-3 3.014E-2
1.964E-1
1.000E0
 1 74
45 hsa-miR-6870-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.131E-3 3.014E-2
1.964E-1
1.000E0
 1 74
46 hsa-miR-6829-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.213E-3 3.014E-2
1.964E-1
1.000E0
 1 75
47 AGGGCCA,MIR-328:MSigDB AGGGCCA,MIR-328:MSigDB MSigDB 6.213E-3 3.014E-2
1.964E-1
1.000E0
 1 75
48 hsa-miR-323a-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.213E-3 3.014E-2
1.964E-1
1.000E0
 1 75
49 hsa-miR-323-5p:PITA hsa-miR-323-5p:PITA TOP PITA 6.378E-3 3.014E-2
1.964E-1
1.000E0
 1 77
50 hsa-miR-5572:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 6.378E-3 3.014E-2
1.964E-1
1.000E0
 1 77
Show 45 more annotations

17: Drug [Display Chart] 6 input genes in category / 2202 annotations before applied cutoff / 22841 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 ctd:C534883 10074-G5 CTD 5.751E-8 1.266E-4 1.048E-3 1.266E-4 2 2
2 CID000331145 NSC321470 Stitch 3.450E-7 3.798E-4 3.143E-3 7.596E-4 2 4
3 CID000092428 cde1 Stitch 8.622E-7 6.328E-4 5.236E-3 1.899E-3 2 6
4 ctd:C524814 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one CTD 3.159E-6 1.739E-3 1.439E-2 6.957E-3 2 11
5 ctd:C050414 tripterine CTD 4.352E-6 1.917E-3 1.586E-2 9.584E-3 3 139
6 1988 UP Captopril [62571-86-2]; Up 200; 17.2uM; HL60; HG-U133A Broad Institute CMAP Up 1.166E-5 4.279E-3 3.541E-2 2.567E-2 3 193
7 CID000162740 bisnortilidine Stitch 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
8 ctd:C021096 tetra(4-N-methylpyridyl)porphine CTD 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
9 CID006443313 AC1O5YTB Stitch 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
10 ctd:C428143 2-(3-estrone-N-ethyl-piperazine-methyl)tetracycline CTD 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
11 CID005376187 sorbicillin Stitch 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
12 CID006439441 KNK-41 Stitch 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
13 ctd:C499730 5,10,15,20-(etra(N-methyl-3-pyridyl))-26,28-diselenasapphyrin chloride CTD 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
14 ctd:C582521 (arginine)9-cysteinyl-glutaminyl-cysteinyl-arginyl-arginyl-lysyl-asparagine CTD 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
15 CID002310442 ap1-20 Stitch 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
16 ctd:D009841 Oligonucleotides CTD 2.627E-4 2.709E-2
2.241E-1
5.784E-1
 1 1
17 ctd:C023013 17 alpha-iodoethynylestradiol CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
18 ctd:C576532 2-(2-(3,5-difluorophenyl)-acetylamino)-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo(e)(1,4)diazepin-3-yl)propionamide CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
19 CID000126798 Ethazolastone Stitch 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
20 ctd:C048336 3-adenin-9-yl-2-hydroxypropanoic acid isobutyl ester CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
21 ctd:C033706 tiazofurin CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
22 CID000328773 NSC308848 Stitch 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
23 ctd:C531092 Shuangling Fuzheng anticancer preparation CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
24 ctd:C070441 pivalyloxymethyl butyrate CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
25 ctd:C059356 5-fluoropyrimidin-2-one beta-ribofuranoside CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
26 ctd:C016391 9-(2,3-dihydroxypropyl)adenine CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
27 ctd:C061022 bullatacin CTD 5.253E-4 2.709E-2
2.241E-1
1.000E0
 1 2
28 CID006439189 KYN-54 Stitch 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
29 ctd:C020924 phenylalanyl-prolyl-arginine methyl chloride CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
30 CID000001644 AC1L1BWX Stitch 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
31 ctd:C521094 N'-(10H-indolo(3,2-b)quinolin-11-yl)-N,N-dimethylpropane-1,3-diamine CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
32 ctd:D009705 Nucleosides CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
33 ctd:C455846 aluminum citrate CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
34 ctd:C533237 STA 9090 CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
35 ctd:C032707 chlorodibromomethane CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
36 ctd:C510786 5-nitroso-8-quinolinol CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
37 ctd:C512984 RO 3306 CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
38 ctd:D009579 Nitrobenzoates CTD 7.879E-4 2.709E-2
2.241E-1
1.000E0
 1 3
39 ctd:D009638 Norepinephrine CTD 8.290E-4 2.709E-2
2.241E-1
1.000E0
 2 172
40 1398 DN Dihydroergotamine tartrate [5989-77-5]; Down 200; 3uM; HL60; HG-U133A Broad Institute CMAP Down 8.974E-4 2.709E-2
2.241E-1
1.000E0
 2 179
41 331 DN trichostatin A; Down 200; 0.1uM; MCF7; HG-U133A Broad Institute CMAP Down 8.974E-4 2.709E-2
2.241E-1
1.000E0
 2 179
42 1076 DN ICI 182,780; Down 200; 0.01uM; MCF7; HT HG-U133A EA Broad Institute CMAP Down 9.073E-4 2.709E-2
2.241E-1
1.000E0
 2 180
43 5202 DN ICI 182,780; Down 200; 1uM; MCF7; HT HG-U133A Broad Institute CMAP Down 9.073E-4 2.709E-2
2.241E-1
1.000E0
 2 180
44 2007 DN Bromocryptine mesylate [22260-51-1]; Down 200; 5.4uM; HL60; HG-U133A Broad Institute CMAP Down 9.174E-4 2.709E-2
2.241E-1
1.000E0
 2 181
45 2423 DN Digoxin [20830-75-5]; Down 200; 5.2uM; HL60; HT HG-U133A Broad Institute CMAP Down 9.376E-4 2.709E-2
2.241E-1
1.000E0
 2 183
46 2620 DN Amoxicillin [26787-78-0]; Down 200; 11uM; MCF7; HT HG-U133A Broad Institute CMAP Down 9.580E-4 2.709E-2
2.241E-1
1.000E0
 2 185
47 1548 DN Retinoic acid [302-79-4]; Down 200; 13.4uM; HL60; HG-U133A Broad Institute CMAP Down 9.683E-4 2.709E-2
2.241E-1
1.000E0
 2 186
48 2192 DN Helveticoside [630-64-8]; Down 200; 7.4uM; HL60; HT HG-U133A Broad Institute CMAP Down 9.683E-4 2.709E-2
2.241E-1
1.000E0
 2 186
49 1555 DN Clonidine hydrochloride [4205-91-8]; Down 200; 15uM; HL60; HG-U133A Broad Institute CMAP Down 9.683E-4 2.709E-2
2.241E-1
1.000E0
 2 186
50 6872 DN ICI182,780; Down 200; 1uM; MCF7; HT HG-U133A Broad Institute CMAP Down 9.787E-4 2.709E-2
2.241E-1
1.000E0
 2 187
Show 45 more annotations

18: Disease [Display Chart] 6 input genes in category / 377 annotations before applied cutoff / 16205 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 C3489626 Cerebelloparenchymal Disorder V DisGeNET BeFree 1.142E-6 4.305E-4 2.803E-3 4.305E-4 2 5
2 C2931456 Prostate cancer, familial DisGeNET Curated 1.389E-4 7.754E-3
5.048E-2
5.235E-2
 2 50
3 C2049069 Indolent multiple myeloma DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
4 C1333063 Classical Burkitt Lymphoma DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
5 C1335482 Gastric Burkitt Lymphoma DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
6 C1332201 Adult Diffuse Large B-Cell Lymphoma DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
7 cv:C1865289 Hyperlipidemia, combined, 1 Clinical Variations 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
8 C4086965 Woodchuck Hepatocellular Carcinoma DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
9 C3824769 Lymphomas in children DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
10 C1265730 Progonoma DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
11 C4024934 Cerebellar medulloblastoma DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
12 cv:C1708353 Hereditary Paraganglioma-Pheochromocytoma Syndromes Clinical Variations 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
13 OMIN:113970 BURKITT LYMPHOMA; BL OMIM 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
14 cv:C0006413 Burkitt lymphoma Clinical Variations 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
15 OMIN:602491 HYPERLIPIDEMIA, COMBINED, 1 OMIM 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
16 C0154064 Carcinoma in situ of anus DisGeNET BeFree 3.703E-4 7.754E-3
5.048E-2
1.396E-1
 1 1
17 C0030421 Paraganglioma DisGeNET Curated 3.836E-4 7.754E-3
5.048E-2
1.446E-1
 2 83
18 C0014170 Endometrial Neoplasms DisGeNET Curated 3.929E-4 7.754E-3
5.048E-2
1.481E-1
 2 84
19 C0751606 Adult Acute Lymphocytic Leukemia DisGeNET BeFree 6.487E-4 7.754E-3
5.048E-2
2.446E-1
 2 108
20 C2004493 Leukemia, B-Cell DisGeNET BeFree 6.487E-4 7.754E-3
5.048E-2
2.446E-1
 2 108
21 C4280289 Lesion of oral cavity DisGeNET Curated 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
22 C0024306 Lymphoma, Undifferentiated DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
23 C0854893 Angiosarcoma non-metastatic DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
24 C1335661 Radiation-Related Angiosarcoma DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
25 C0205833 Medullomyoblastoma DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
26 C0278836 Stage III Prostate Carcinoma DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
27 OMIN:144250 HYPERLIPIDEMIA, FAMILIAL COMBINED; FCHL OMIM 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
28 C2985220 Anaplastic Medulloblastoma DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
29 C1334633 Mature B-Cell Neoplasm DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
30 20081125:Kiemeney Urinary bladder cancer GWAS 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
31 C0026773 Multiple Personality Disorder DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
32 C0206094 Neuroectodermal Tumor, Melanotic DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
33 C0558348 Bacterial gastroenteritis DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
34 C0266566 Optic disc structural anomaly DisGeNET BeFree 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
35 C0149744 Oral lesion DisGeNET Curated 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
36 C4073168 Abnormal lactate dehydrogenase activity DisGeNET Curated 7.404E-4 7.754E-3
5.048E-2
2.791E-1
 1 2
37 C0334385 Inflammatory carcinoma DisGeNET BeFree 1.110E-3 1.047E-2
6.814E-2
4.186E-1
 1 3
38 C0345960 Giant cell carcinoma of lung DisGeNET BeFree 1.110E-3 1.047E-2
6.814E-2
4.186E-1
 1 3
39 C2733623 Fibrosarcoma of bone DisGeNET BeFree 1.110E-3 1.047E-2
6.814E-2
4.186E-1
 1 3
40 C0023453 Leukemia, Lymphocytic, Acute, L2 DisGeNET BeFree 1.110E-3 1.047E-2
6.814E-2
4.186E-1
 1 3
41 C0279821 metastatic pheochromocytoma DisGeNET BeFree 1.480E-3 1.240E-2
8.075E-2
5.581E-1
 1 4
42 C0740479 Undifferentiated High Grade Pleomorphic Sarcoma of Bone DisGeNET BeFree 1.480E-3 1.240E-2
8.075E-2
5.581E-1
 1 4
43 C2853919 Lymphoblastic B-cell lymphoma DisGeNET BeFree 1.480E-3 1.240E-2
8.075E-2
5.581E-1
 1 4
44 C0456863 High grade B-cell lymphoma DisGeNET BeFree 1.480E-3 1.240E-2
8.075E-2
5.581E-1
 1 4
45 C2981712 Ocular Adnexal Lymphoma DisGeNET BeFree 1.480E-3 1.240E-2
8.075E-2
5.581E-1
 1 4
46 C4021634 Abnormality of bone marrow cell morphology DisGeNET Curated 1.850E-3 1.484E-2
9.662E-2
6.975E-1
 1 5
47 C0334355 Serous cystadenoma, borderline malignancy DisGeNET BeFree 1.850E-3 1.484E-2
9.662E-2
6.975E-1
 1 5
48 C1867300 RETINITIS PIGMENTOSA 9 DisGeNET Curated 2.589E-3 1.842E-2
1.199E-1
9.762E-1
 1 7
49 20090330:Polasek Anthropometric traits GWAS 2.589E-3 1.842E-2
1.199E-1
9.762E-1
 1 7
50 C0006160 Brenner Tumor DisGeNET BeFree 2.589E-3 1.842E-2
1.199E-1
9.762E-1
 1 7
Show 45 more annotations